Drug Profile
Research programme: Helicobacter pylori and Chlamydia pneumoniae infection therapies - ALTANA Pharma/GPC Biotech
Latest Information Update: 27 Apr 2004
Price :
$50
*
At a glance
- Originator ALTANA Pharma; GPC Biotech AG
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chlamydial infections; Helicobacter infections
Most Recent Events
- 27 Apr 2004 Discontinued - Preclinical for Chlamydial infections in USA (unspecified route)
- 27 Apr 2004 Discontinued - Preclinical for Helicobacter infections in USA (unspecified route)
- 08 Jul 2002 Byk Gulden is now called Altana Pharma